{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:40:55Z","timestamp":1791463255691,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jogc.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jogc.2025.103191","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:51:20Z","timestamp":1764391880000},"page":"103191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of Maternal Periconceptional Exposure to Glucagon-Like Peptide-1 Receptor Agonists: A Scoping Review of Evidence and Reporting Trends"],"prefix":"10.1016","volume":"48","author":[{"given":"In Ok","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ghiasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8974-4548","authenticated-orcid":false,"given":"Mark","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogc.2025.103191_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2025.103191_bib2","series-title":"An overview of weight and height measurements on World Obesity Day","year":"2024"},{"key":"10.1016\/j.jogc.2025.103191_bib3","series-title":"Health characteristics, annual estimates, inactive","year":"2023"},{"key":"10.1016\/j.jogc.2025.103191_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.2026","article-title":"Prescription fills for semaglutide products by payment method","volume":"5","author":"Scannell","year":"2024","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.jogc.2025.103191_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41367-019-0009-1","article-title":"Female infertility: which role for obesity?","volume":"9","author":"Gambineri","year":"2019","journal-title":"Int J Obes"},{"key":"10.1016\/j.jogc.2025.103191_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cob.12048","article-title":"Weight loss improves reproductive outcomes in obese women undergoing fertility treatment: a randomized controlled trial","volume":"4","author":"Sim","year":"2014","journal-title":"Clin Obes"},{"key":"10.1016\/j.jogc.2025.103191_bib7","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jogc.2025.103191_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jogc.2025.103191_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jogc.2025.103191_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","volume":"232","author":"Drummond","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogc.2025.103191_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1728-4465.2010.00250.x","article-title":"Unintended pregnancy: worldwide levels, trends, and outcomes","volume":"41","author":"Singh","year":"2010","journal-title":"Stud Fam Plann"},{"key":"10.1016\/j.jogc.2025.103191_bib12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.11124\/JBIES-21-00242","article-title":"Best practice guidance and reporting items for the development of scoping review protocols","volume":"20","author":"Peters","year":"2022","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.jogc.2025.103191_bib13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jogc.2025.103191_bib14","series-title":"Covidence Systematic Review Software","year":"2019"},{"key":"10.1016\/j.jogc.2025.103191_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/TEN.0b013e3181a5875e","article-title":"Case report: exenatide use during pregnancy","volume":"19","author":"Williams","year":"2009","journal-title":"Endocrinologist"},{"key":"10.1016\/j.jogc.2025.103191_bib16","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/dme.12726","article-title":"Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with type 2 diabetes","volume":"32","author":"Greco","year":"2015","journal-title":"Diabet Med"},{"key":"10.1016\/j.jogc.2025.103191_bib17","first-page":"70","article-title":"Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report","volume":"27","author":"Ivani\u0161evi","year":"2018","journal-title":"Gynaecol Perinatol"},{"key":"10.1016\/j.jogc.2025.103191_bib18","first-page":"19","article-title":"Liraglutide administration improves hormonal\/metabolic profile and reproductive features in women with HAIR-AN syndrome","volume":"2020","author":"Livadas","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.jogc.2025.103191_bib19","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.eprac.2023.03.056","article-title":"Abstract #1407760: case study: a challenging case of management of pre-existing type 2 diabetes mellitus during pregnancy in a patient with multiple insulin allergies","volume":"29","author":"Shahid","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jogc.2025.103191_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00592-022-01954-4","article-title":"A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus","volume":"60","author":"Burlina","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jogc.2025.103191_bib21","article-title":"A case report of a pregnant woman with type 2 diabetes mellitus using dulaglutide during the first trimester of pregnancy","volume":"15","author":"Alghamdi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jogc.2025.103191_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijgo.15092","article-title":"Semaglutide and pregnancy","volume":"163","author":"Skov","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jogc.2025.103191_bib23","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/0118715303252109231023115112","article-title":"Case series: exposure to glucagon-like peptide-1 receptor agonist in the first trimester of pregnancy in two siblings","volume":"24","author":"Do\u011fan","year":"2024","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.jogc.2025.103191_bib24","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00592-024-02331-z","article-title":"Use of dulaglutide in a pregnant woman with type 2 diabetes until third trimester of pregnancy","volume":"61","author":"Molteni","year":"2024","journal-title":"Acta Diabetol"},{"issue":"Suppl 1","key":"10.1016\/j.jogc.2025.103191_bib25","article-title":"GLP-1 receptor agonist treatment in early pregnancy and risk of pregnancy complications - a nationwide cohort study","volume":"39","author":"Hviid","year":"2024","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jogc.2025.103191_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jogc.2025.103191_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1467-789X.2008.00537.x","article-title":"Obesity as an independent risk factor for elective and emergency caesarean delivery in nulliparous women \u2013 systematic review and meta-analysis of cohort studies","volume":"10","author":"Poobalan","year":"2009","journal-title":"Obes Rev"},{"key":"10.1016\/j.jogc.2025.103191_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.beem.2010.05.011","article-title":"Type 2 diabetes in pregnancy \u2013 an increasing problem","volume":"24","author":"Temple","year":"2010","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216325004372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216325004372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:07:22Z","timestamp":1768522042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216325004372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1701216325004372"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2025.103191","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Maternal Periconceptional Exposure to Glucagon-Like Peptide-1 Receptor Agonists: A Scoping Review of Evidence and Reporting Trends","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2025.103191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103191"}}